Adding immunotherapy and a targeted drug around bladder surgery helped people live longer
In the VOLGA trial, published Oct. 24, 2026, in NEJM, people with muscle-invasive bladder cancer who couldn't get cisplatin had better event-free and overall survival when durvalumab and enfortumab vedotin were added…